Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Pres. Restrictions Dosage
361 Clopidogrel 75 mg Tablet B01AC04192T1001XX A/KK Secondary prevention of atherothrombotic events in: i) Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Prescribing restriction: as second/third line treatment in patients who are sensitive or intolerant to acetylsalicylic acid and/or ticlopidine). ii) Adult patients suffering from acute coronary syndrome: • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention. • ST segment elevation acute myocardial infarction, in combination with acetylsalicylate acid (ASA) in medically treated patients eligible for thrombolytic therapy. 75 mg once daily
362 Clostridium Botulinum Toxin Type A 100 units M03AX01000P4001XX A* i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy 20 - 200 units 3 months once
363 Clostridium Botulinum Type A toxin haemagglutinin complex 300 units/vial powder for injection M03AX01000P4003XX A* i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy Initially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.
364 Clostridium botulinum Type A toxin haemagglutinin complex 500U/vial powder for injection M03AX01000P4002XX A* i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy Initially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.
365 Clotrimazole 1% Cream D01AC01000G1001XX B Cutaneous candidiasis, Tinea corporis, Tinea cruris, Tinea pedis and Tinea versicolor Rub in gently onto affected and surrounding skin 2 or 3 times daily continuing for about 2 weeks beyond the dissapearance of all symptoms
366 Clotrimazole 1% Ear Drop S02AA00000D1002XX B Otomycosis; concomitant therapy with antibiotics and corticosteroid ear drops 4 to 5 drops 3 to 4 times daily
367 Clotrimazole 1% Solution D01AC01000L6001XX A Cutaneous candidiasis, tinea orporis, tinea cruris, tinea pedis and tinea versicolor Apply gently onto affected and surrounding skin area 2 or 3 times daily continuing for 2-4 weeks
368 Clotrimazole 500 mg Vaginal Tablet G01AF02000S1003XX B Vaginal candidiasis 500 mg as a single one-time dose
369 Cloxacillin Sodium 125 mg/5 ml Suspension J01CF02520L8001XX B Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci Child: 50-100 mg/kg in divided doses every 6 hr
370 Cloxacillin Sodium 250 mg Capsule J01CF02520C1001XX B Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr.
371 Cloxacillin Sodium 250 mg Injection J01CF02520P4001XX B Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infections ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours
372 Cloxacillin Sodium 500 mg Capsule J01CF02520C1002XX B Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr.
373 Cloxacillin Sodium 500 mg Injection J01CF02520P4002XX B Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infections ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours
374 Clozapine 100 mg Tablet N05AH02000T1002XX A Treatment of resistant schizophrenia Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
375 Clozapine 25 mg Tablet N05AH02000T1001XX A Treatment of resistant schizophrenia Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
376 Coal Tar 1-9% Ointment D05AA00000G5001XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis. Used as a mild astringent for the skin, as a soothing and protective application in eczema and as a protective to slight excoriation Apply sparingly to the affected area 1-3 times daily starting with low strength preparations
377 Coal Tar 20% Solution D05AA00000L5201XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis Use 100 ml in a bath
378 Coal Tar and Salicylic Acid (various concentrations) Ointment D05AA00946G5002XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis Apply to the affected areas
379 Coal Tar with Salicylic Acid (various concentrations) Solution D05AA00000L5202XX B Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis Apply to the affected areas or as in product leaflet
380 Cocaine 10% Solution N01BC01110L5001XX B To produce local anaesthesia or vasoconstriction during endoscopic nasal surgery, turbinectomy septoplasty, polypectomy etc Maximum total dose recommended for application to the nasal mucosa in healthy adult is 1.5 to 2 mg/kg of a 10% cocaine solution
381 Cocois Co. Ointment D05AA00946G5001XX B Scalp psoriasis and severe seborrhoeic dermatitis Rub a small amount into the scalp gently
382 Colchicine 0.5 mg Tablet M04AC01000T1001XX B i) Acute gout and prophylaxis of recurrent gout. ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitis i) Initial dose, 1 mg, then 0.5 mg after 1 hour. No further tablets should be taken for 12 hours. After 12 hours, treatment can resume if necessary with a maximum dose of 500 micrograms (1 tablet) every 8 hours until symptoms are relieved. The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken. No more than 6 mg (12 tablets) should be taken as a course of treatment. After completion of a course, another course should not be started for at least 3 days (72 hours). ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day
383 Colistimethate Sodium 1 million IU per vial (Polymyxin E) J01XB01520P4001XX A* Intravenous administration for the treatment of serious infections caused by Gram negative bacteria, when more commonly used systemic antibacterial agents may be contraindicated or may be ineffective because of bacterial resistance. A minimum of 5 days treatment is generally recommended. For the treatment of respiratory exacerbations in cystic fibrosis patients, treatment should be continued up to 12 days. Children and adults (including elderly): Up to 60kg: 50,000 units/kg/day to a maximum of 75,000 units/kg/day. The total daily dose should be divided into three doses given at approximately 8-hour intervals. Over 60kg: 1-2 million units three times a day. The maximum dose is 6 million units in 24 hours. Renal impairment: In moderate to severe renal impairment, excretion of colistimethate sodium is delayed. Dosage in Renal Impairment (for over 60 kg body weight): - Mild (CrCl 20-50 ml/min): 1-2 million units every 8 hr. - Moderate (CrCl 10-20 ml/min): 1 million units every 12-18 hr. - Severe (CrCl <10 ml/min): 1 million units every 18-24 hr.
384 Colloidal Bismuth Subcitrate 120 mg Tablet A02BX05136T1001XX A Eradication therapy for Helicobacter Pylori in combination with antibiotics and antisecretory drugs 240 mg twice daily for 1-2 weeks
385 Compound Sodium Lactate (Hartmanns Solution) B05XA30125P6001XX C Replacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent 100-1000 ml by IV or according to the needs of the patient
386 Conjugated estrogens 0.3 mg Tablet G03CA57000T1003XX A i) Osteoporosis associated with oestrogen deficiency ii) Female hypoestrogenism iii) Vasomotor symptoms associated with oestrogen deficiency iv)atrophic vaginitis and urethritis i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily
387 Conjugated Estrogens 0.625 mg & Medroxyprogesterone Acetate 2.5 mg Tablet G03FA12295T1002XX A Management of moderate to severe vasomotor symptoms associated with menopause, prevention and management of postmenopausal osteoporosis, atropic vaginitis and atropic urethritis in post menopausal woman with intact uterus 1 tablet daily
388 Conjugated Oestrogens 0.625 mg Tablet G03CA57000T1001XX A i) Osteoporosis associated with oestrogen deficiency ii) Female hypoestrogenism iii) Vasomotor symptoms associated with oestrogen deficiency iv)atrophic vaginitis and urethritis i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily
389 Conjugated Oestrogens 0.625 mg/g Cream G03CA57000G1001XX A Atrophic vaginitis and post menopausal atrophic urethritis Intravaginally or topically 0.5-2g daily depending on severity of condition. Administration should be cyclic, with 3 weeks on conjugated estrogens and one week off. Estrogens should be used for the shortest duration possible when treating atrophic vaginitis. Every 3 to 6 months attempts should be made to taper or discontinue therapy and conjugated estrogens should be titrated to give the lowest possible dosage to control symptoms
390 Continuous Ambulatory Peritoneal Dialysis (CAPD) Solution containing 2.3% glucose (Calcium 1.75mmol/L) & (Calcium 1.25mmol/L) B05DB00908H2504XX B For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre Dose depending on clinical cases

Halaman-halaman